ENDRA Life Sciences Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
NDRA$4.77-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to Financial Statements
ENDRA Life Sciences Inc.
December 31, 2025
| Page | |
| Report of Independent Registered Public Accounting Firm - (Firm ID 587) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements for the years ended December 31, 2025 and 2024 | F-8 |
RBSM LLP Houston Office: 7915 FM 1960 West, Ste. 220 Houston, Texas 77070 www.rbsmllp.com
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.